Optinose to Present at the Jefferies Virtual Healthcare Conference
June 01, 2021 09:00 ET
|
Optinose, Inc.
YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports First Quarter 2021 Financial Results and Operational Updates
May 05, 2021 07:00 ET
|
Optinose, Inc.
Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be...
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
April 28, 2021 08:30 ET
|
Optinose, Inc.
Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 YARDLEY, Pa., April 28, 2021...
Optinose to Present at the Needham Virtual Healthcare Conference
April 12, 2021 16:15 ET
|
Optinose, Inc.
YARDLEY, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
March 03, 2021 07:00 ET
|
Optinose, Inc.
Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company...
Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results
February 17, 2021 17:23 ET
|
Optinose, Inc.
Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time Company to Present at the Cowen 41st Annual Health Care Conference on March 4, 2021 YARDLEY, Pa., Feb. 17, 2021 ...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 25, 2021 16:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2020 10:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose Announces Changes to Board of Directors
December 01, 2020 16:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
November 05, 2020 07:00 ET
|
Optinose, Inc.
Company reports third quarter 2020 XHANCE net revenue of $15.4 million New prescriptions of XHANCE increased 23% from second quarter 2020 Conference call and webcast to be held today at 8:00 a.m....